NMN medical composition for AD treatment

A composition and drug technology, applied in the field of medicine, can solve problems such as high drug concentration, high manufacturing cost, and limited clinical promotion and application

Inactive Publication Date: 2020-10-13
深圳市旷逸生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its high manufacturing cost and ultra-high drug concentration (0.6-2g / person / day) limit clinical promotion and application, so reducing manufacturing costs or reducing drug concentration has become the key to using NMN for AD treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NMN medical composition for AD treatment
  • NMN medical composition for AD treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The preparation of embodiment 1 alpine edelweiss extract

[0033] Accurately weigh 1000g of alpine edelweiss plant cell culture (moisture content above 90%), after fully suspending, add 2000mL of 95% ethanol at a material-to-liquid ratio of 1:2 (m / v), stir and mix, and ultrasonically treat 15min (ultrasonic power: 300w, ultrasonic temperature: 25°C); add 8L of pure water to the ultrasonically broken wall treatment product, and extract at a high temperature of 80-120°C for 1.5h; centrifuge the extracted product at 10,000g for 10min to take the supernatant, The supernatant was concentrated under reduced pressure and then freeze-dried to obtain the edelweiss alpine extract.

Embodiment 2

[0034] The preparation of embodiment 2 pharmaceutical compositions

[0035] After accurately weighing 4g of NMN and 80g of alpine edelweiss extract and mixing them uniformly in equal proportions, the pharmaceutical composition is obtained.

Embodiment 3

[0036] Example 3 Study and cognitive intervention experiment of pharmaceutical composition on Tg2576 transgenic mice

[0037] Experimental Materials:

[0038] 1) Experimental animals: 48 8-week-old Tg2576 transgenic male mice, 8 8-week-old C57BL / 6J male mice with the same genetic background, all purchased from Saiye (Suzhou) Biotechnology Co., Ltd. Housing group temporary care.

[0039] 2) Test drugs:

[0040] The pharmaceutical composition prepared in Example 2 of the present invention;

[0041] NMN: Bangtai Bioengineering (Shenzhen) Co., Ltd.

[0042] 3) Main experimental instruments

[0043] Morris water maze system (including camera and analysis system) was purchased from Shanghai Ruanlong Technology Development Co., Ltd.

[0044] 4) Experimental method:

[0045] grouping:

[0046] 48 Tg2576 transgenic male mice were randomly divided into 6 groups, extract group 1, extract group 2, drug group, NMN control group, NMN control group 2 and blank control group, 8 mice in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medical composition. The medical composition consists of NMN, a leontopodium alpinum extract and pharmaceutically acceptable auxiliary materials. The medical composition isused for restraining oxidative stress injury in progress of generation and development of AD. The leontopodium alpinum extract can notably increase transmission of choline in brains; when the leontopodium alpinum extract and the NMN are combined for use, the medication concentration of the NMN in AD treatment can be notably reduced, and clinical application and promotion of the NMN for treating the AD can be feasible.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically, the invention provides a pharmaceutical composition containing NMN for AD treatment, which is used for inhibiting oxidative stress damage in the development process of AD. Background technique [0002] Alzheimer's disease (AD) is a complex multifunctional disorder characterized by memory loss and impairment of various cognitive functions. Several therapeutic strategies have been developed to treat AD including anti-inflammatory, anti-oxidative and anti-amyloid approaches. Oxidative stress is an important factor in the development of AD and other forms of dementia. A large number of data show that free radical oxygen damage, especially neuronal liposomes, proteins and nucleic acids, exists widely in the brains of AD patients. [0003] Studies have found that NMN can improve the cognitive and memory functions of Alzheimer's disease rats caused by Aβ1-42 oligomers by improving e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/28A61K31/706A61P25/28A61P39/00
CPCA61K31/706A61K36/28A61K2236/30A61P25/28A61P39/00A61K2300/00
Inventor 沈洁
Owner 深圳市旷逸生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap